Cubist Leadership Transitions To Perez With ‘Strong Hand To Play’
This article was originally published in The Pink Sheet Daily
President and Chief Operating Officer Robert Perez will succeed Michael Bonney as CEO effective Jan. 1, taking over the top leadership spot at a time when the specialty pharma is in the midst of a transformation into a multi-asset company.
You may also be interested in...
Cubist Sets Sights On European Antibiotics Market With Zurich Move: A Conversation With Patrick Vink
Cubist recently has seen its key antibiotic Cubicin become a blockbuster in the U.S. It is determined to take this success, backed by a flourishing pipeline, to answer Europe's call for products to fight antimicrobial resistance.
Cubist will rely on its experience in infectious disease to drive growth of Dificid for Clostridium difficile infection and to launch tedizolid for skin infections, but the commercial market for new antibiotics is daunting and re-creating the success of Cubicin won’t be easy.
Cubist has focused on marketing its sole drug, Cubicin, since the antibiotic was approved in 2003, but through business development and clinical progress, the biopharma is in the midst of a transformation.